

section of this announcement. Measures must be objective and quantitative and must measure the intended outcome. The measures of effectiveness must be submitted with the application and will be an element of evaluation.

An independent review group appointed by CDC will evaluate each application against the following criteria:

1. The adequacy of the operational plans for carrying out the various initiatives involved in the project. (30 points)
2. The extent to which professional personnel proposed to be involved in this project are qualified, including evidence of past achievements appropriate to this project (20 points)
3. The degree to which the proposed objectives are clearly stated, realistic, time-phased, and related to the purpose of the project. (15 points)
4. The quality and feasibility of the evaluation plan for the various initiatives involved in the project. (15 points)
5. The extent to which the applicant understands the requirements, problems, objectives and complexities of the project. (10 points)
6. The extent to which the applicant proposes potentially effective coordination with state/local health departments. (10 points)
7. Budget and its description. The applicant must provide justification for budget expenditures as well as appropriateness of activities proposed in their application. (Not scored)

I. Other Requirements

Technical Reporting Requirements

Provide CDC with original plus two copies of

1. Interim progress report, which will be due on April 22nd of each budget year. The progress report will serve as your non-competing continuation application, and must contain the following elements:
 - a. Current Budget Period Activities Objectives;
 - b. Current Budget Period Financial Progress;
 - c. New Budget Period Program Proposed Activity and Objectives;
 - d. Detailed Line-Item Budget and Justification; and
 - e. Additional Requested Information.
 2. Financial status report, due no more than 90 days after the end of the budget period (December 30th of each budget year); and
 3. Final financial and performance reports, no more than 90 days after the end of the project period.
- Send all reports to the Grants Management Specialist identified in the

“Where to Obtain Additional Information” section of this announcement.

Additional Requirements

The following additional requirements are applicable to this program. For a complete description of each, see Attachment I of the announcement, as posted on the CDC web site.

AR-09 Paperwork Reduction Act

AR-10 Smoke-Free Workplace Requirements

AR-11 Healthy People 2010

AR-12 Lobbying Restrictions

AR-14 Accounting System Requirements

AR-15 Proof of Non-Profit Status

Executive Order 12372 does not apply.

J. Where to Obtain Additional Information

This and other CDC announcements can be found on the CDC home page Internet address—<http://www.cdc.gov>. Click on “Funding” then “Grants and Cooperative Agreements.”

For general questions about this announcement, contact: Technical Information Management, CDC Procurement and Grants Office, 2920 Brandywine Road, Atlanta, GA 30341–4146, Telephone: 770–488–2700.

For business management technical assistance, contact: Sheryl Heard, Grants Management Specialist, Acquisition and Assistance Branch B., Procurement and Grants Office, Centers for Disease Control and Prevention, 2920 Brandywine Road, Room 3000, Atlanta, GA 30341–4146. Telephone number: 770–488–2723. Email: slh3@cdc.gov.

For program technical assistance, contact: Hani Atrash, Associate Director for Program Development, National Center on Birth Defects and Developmental Disabilities, 4770 Buford Highway, Atlanta, Georgia 30341, Telephone number: 770–488–4943, Email: hka1@cdc.gov.

Dated: May 15, 2003.

Sandra R. Manning,

Director, Procurement and Grants Office,
Centers for Disease Control and Prevention.
[FR Doc. 03–12709 Filed 5–20–03; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement 03070]

Surveillance and Epidemiologic Research of Duchenne and Becker Muscular Dystrophy; Notice of Availability of Funds

Application Deadline: July 21, 2003.

A. Authority and Catalog of Federal Domestic Assistance Number

This program is authorized under Sections 301, 311 and 317C of the Public Health Service Act [42 U.S.C. 241, 243, and 247b–4 as amended]. The Catalog of Federal Domestic Assistance number is 93.184.

B. Purpose

The Centers for Disease Control and Prevention (CDC) announces the availability of fiscal year (FY) 2003 funds for a cooperative agreement program on surveillance and epidemiologic research of Duchenne and Becker Muscular Dystrophy (DBMD). This Program addresses the “Healthy People 2010” focus areas for Disability and Secondary Conditions.

The purpose of the program is to support (1) the development and/or expansion of active case ascertainment surveillance systems to characterize the epidemiology of DBMD and its complications; and (2) the participation of the state DBMD surveillance system in the Collaborative DBMD Project. Long-term population-based follow-up research activities will be planned to describe history of treated and/or untreated cases, and to determine factors that affect outcome of the condition among three populations: (a) Those who access care at specialty clinics (e.g., Muscular Dystrophy Association (MDA) or other muscular dystrophy clinics), (b) those who receive their care elsewhere, and (c) those who are not receiving care or are undiagnosed. See Attachment I for Background and Definitions. All attachments referenced in this announcement are posted with the announcement on the CDC Web site.

Measurable outcomes of this program will be in alignment with the following performance goal for the National Center for Birth Defects and Developmental Disabilities (NCBDDD): to find causes and risk factors for birth defects and developmental disabilities in order to develop prevention strategies.